"The second quarter was an important one on many fronts, from advancing our pipeline with the clearance of our second investigational new drug application, to designing our state-of-the-art manufacturing facility and the continued onboarding of highly-skilled employees who are passionate about bringing allogeneic
cell therapy to patients," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.
M2 PHARMA-June 13, 2019-Viralym-M Granted Regenerative Medicine Advanced Therapy Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic
WARREN, N.J., March 29, 2019 -- Celgene spinout company Celularity, Inc., announced results from two Phase 1 studies of PNK-007, an investigational allogeneic
off-the-shelf natural killer (NK) cell therapy, in patients with acute myeloid leukemia (AML) and in patients with multiple myeloma (MM).
Cryoport, a temperature-controlled logistics company, has been selected by allogeneic
cell therapy company, Celularity, to utilize its complete range of temperature-controlled solutions.
The FDA approved a Phase 2 clinical trial using an allogeneic
mesenchymal stem cell-based drug, the first in Taiwan and in Asia to obtain the second Phase of U.S.
FDA approved the company's second -Phase clinical implementation of a new drag using allogeneic
mesenchymal stem cells.
SR-aGvHD is a leading cause of death following an allogeneic
stem cell transplant the product is claimed to be differentiated by its high microbial diversity and richness that can restore the patient's functional microbiome with the aim of re-establishing homeostasis.
New Jersey, US-based allogeneic
immune-oncology company Celularity has agreed to acquire Colorado, US-based family cord blood bank CariCord, established by the University of Colorado and ClinImmune Labs, the company said.
8, 2018 (HealthDay News) -- Individuals who underwent allogeneic
blood or marrow transplantation (BMT) in childhood have elevated risk of late mortality 25 years or more after transplantation, according to a study published online July 26 in JAMA Oncology.
Allogene is advancing its allogeneic
CAR T portfolio acquired from Pfizer which included the rights to 16 preclinical CAR T assets licensed from Cellectis and Servier and U.S.
(NYSE: PFE) and Allogene for Pfizer's portfolio of assets related to allogeneic
chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy approach to treating cancer.